These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30192751)

  • 21. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
    Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
    Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Effectiveness of Medical Therapy and Surgical Intervention for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.
    Wang Z; Zhang W; Fan Y; Zhang X
    Cancer Control; 2022; 29():10732748221140266. PubMed ID: 36471546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost MD; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Niolat J; Jóźwiak S
    PLoS One; 2016; 11(6):e0158476. PubMed ID: 27351628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan.
    Hatano T; Chikaraishi K; Inaba H; Endo K; Egawa S
    Int J Urol; 2016 Oct; 23(10):833-838. PubMed ID: 27480662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
    Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
    Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus.
    Zonnenberg BA; Neary MP; Duh MS; Ionescu-Ittu R; Fortier J; Vekeman F
    PLoS One; 2018; 13(11):e0204646. PubMed ID: 30439947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
    Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
    J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis.
    Bujalance-Cabrera C; Vaquero-Barrios JM; Redel-Montero J; Caballero-Ballesteros L; Requejo-Jiménez A; Santos-Luna F
    Arch Bronconeumol; 2012 Dec; 48(12):479-81. PubMed ID: 22444789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphangioleiomyomatosis.
    Johnson SR; Taveira-DaSilva AM; Moss J
    Clin Chest Med; 2016 Sep; 37(3):389-403. PubMed ID: 27514586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
    Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
    Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
    Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
    J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.
    Malinowska IA; Lee N; Kumar V; Thiele EA; Franz DN; Ashwal S; Sagalowsky A; Dimario FJ; Cutler D; Krueger D; Camposano S; Paolini J; Dabora SL
    PLoS One; 2013; 8(2):e56199. PubMed ID: 23437092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
    Gu L; Peng C; Zhang F; Fang C; Guo G
    Orphanet J Rare Dis; 2021 Jun; 16(1):277. PubMed ID: 34127034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus in pregnancy: Case report and literature review.
    Yamamura M; Kojima T; Koyama M; Sazawa A; Yamada T; Minakami H
    J Obstet Gynaecol Res; 2017 Aug; 43(8):1350-1352. PubMed ID: 28557245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal angiomyolipoma and tuberous sclerosis complex: long-term safety and efficacy outcomes of Everolimus therapy.
    Ruiz Guerrero E; Ledo Cepero MJ; Ojeda Claro AV; Soto Delgado M; Álvarez-Ossorio Fernández JL
    Actas Urol Esp (Engl Ed); 2021 May; 45(4):264-272. PubMed ID: 33637375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.
    Liao Z; Li J; Zhao Y; Wang Z; Wang X; Qiu D; Zhang Y
    World J Urol; 2024 Jan; 42(1):10. PubMed ID: 38183428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HUGE RENAL ANGIOMYOLIPOMA (AML) IN TUBEROUS SCLEROSIS COMPLEX (TSC) WHICH IS CONTROLED BY EVEROLIMUS: A CASE REPORT].
    Kanbara T; Sakaeda K; Kusaka N; Akebi N
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):54-58. PubMed ID: 28132993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
    Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
    Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2.
    Kwiatkowski DJ; Palmer MR; Jozwiak S; Bissler J; Franz D; Segal S; Chen D; Sampson JR
    Eur J Hum Genet; 2015 Dec; 23(12):1665-72. PubMed ID: 25782670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.